Advertisement

Aging Clinical and Experimental Research

, Volume 20, Issue 4, pp 280–289 | Cite as

Diabetes and osteoporosis

  • Alois SallerEmail author
  • Stefania Maggi
  • Giovanna Romanato
  • Paolo Tonin
  • Gaetano Crepaldi
Review Article

Abstract

Care of patients with diabetes should include assessment of bone health. The extension of the average life expectancy of people with diabetes, which has accompanied improvements in medical care, has also increased the significance of osteoporosis. In addition to the usual causes of osteoporosis associated with aging, bone health is also compromised by diabetes. Studies on bone involvement in patients with diabetes mellitus have generated conflicting results, largely because of the pathogenetic complexity of the condition. It is now clear that patients with type 1 diabetes have lower bone mineral density (BMD) and a higher risk of fractures. Evidence is emerging that patients with type 2 diabetes who have complications are also at increased risk of certain types of osteoporotic fractures, despite having a higher BMD when compared to patients with type 1 diabetes. Although many factors, including number and type of falls, visual impairment, neuropathy, and reduced muscle strength, influence the probability of fractures, the most significant factor seems to be the strength of the bone itself. Thus, sarcopenia, a reduction in muscle mass and muscle strength, is considered one of the main determinants of bone fragility. The aim of this review is to examine the occurrence of osteoporosis in type 1 and type 2 diabetes.

Key words

Diabetes osteoporosis quality of bone sarcopenia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes; estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–53.PubMedCrossRefGoogle Scholar
  2. 2.
    United Nations Population Division, Department of Economic and Social Affairs. World Urbanization Prospects: 1999 Revision. New York: United Nations Population Division, Department of Economic and Social Affairs, 1999.Google Scholar
  3. 3.
    Harris MI, Regal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988–98. Diabetes Care 1998; 21: 518–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Onkamo P, Väänänen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of Type I diabetes — the analysis of the data on published incidence trends. Diabetologia 1999; 42: 1395–403.PubMedCrossRefGoogle Scholar
  5. 5.
    EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000; 355: 873–6.CrossRefGoogle Scholar
  6. 6.
    Green A, Patterson CC. Trends in the incidence of childhood-onset diabetes in Europe 1989–1998. Diabetologia 2001; 44 (Suppl 3): B3–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Tuomilehto J, Virtala E, Karvonen M, et al. Increase in incidence of insulin-dependent diabetes mellitus among children in Finland. Int J Epidemiol 1995; 24: 984–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Garnder SG, Bingley PJ, Sawtell PA, Weeks S, Gale EA. Rising incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region: time trend analysis. The Bart’s-Oxford Study Group. BMJ 1997; 315: 713–7.CrossRefGoogle Scholar
  9. 9.
    Dahlquist G, Mustonen L. Analysis of 20 years of prospective registration of childhood onset diabetes, time trends, and birth cohort effects. Swedish Childhood Diabetes Study Group. Acta Paediatr 2000; 89: 1231–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000; 136: 664–72.PubMedCrossRefGoogle Scholar
  11. 11.
    International Diabetes Federation. Diabetes atlas, 2nd ED. Brussels: International Diabetes Federation, 2003.Google Scholar
  12. 12.
    World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. Geneva: World Health Organisation, 1994 (Tec. Rep. Ser., n. 843).Google Scholar
  13. 13.
    Looker A, Orwoll E, Johnston CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997; 12: 1761–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Melton LJ, III. Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Metab 2000; 15: 2309–14.CrossRefGoogle Scholar
  15. 15.
    Gullberg B, Johnell O, Kanis J. World-wide projections for hip fracture. Osteoporosis Int 1997; 7: 407–13.CrossRefGoogle Scholar
  16. 16.
    Ray NF, Chan JK, Thamer M, Melton LJKKK. Medical expenditures for the treatment of osteoporotic fracture in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24–35.PubMedCrossRefGoogle Scholar
  17. 17.
    Maggi S, Noale M, Giannini S, et al. Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int 2006; 17: 237–44.PubMedCrossRefGoogle Scholar
  18. 18.
    12a Commissione Permanente del Senato della Repubblica (Igiene e Sanità), sui problemi socio-sanitari connessi alla patologia osteoporotica. Rome: Italian Senate.Google Scholar
  19. 19.
    Albright F, Reifenstein EC. Parathyroid glands and metabolic bone disease. Selected studies. Baltimore: Williams and Wilkins Company, 1948: 150.Google Scholar
  20. 20.
    Meema HE, Meema S. The relationship of diabetes mellitus and body weight to osteoporosis in elderly females. Can Med Ass J 1967; 96: 132–9.PubMedGoogle Scholar
  21. 21.
    Kayath MJ, Tavares EF, Dib SA, Vieria JGH. Prospective bone mineral density evaluation in patients with insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12: 133–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Piepkorn B, Kann P, Forst T, Andreas J, Pfützner A, Beyer J. Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res 1997; 29: 584–91.PubMedCrossRefGoogle Scholar
  23. 23.
    De Leeuw I, Mulkens N, Vertommen J, Abs R. A histo-morphometric study on the trabecular bone of diabetic subjects (Abstract). Diabetologia 1976; 12: 385–6.Google Scholar
  24. 24.
    McNair P, Madsbad S, Christiansen C, Faber OK, Transbol I, Binder C. Osteopenia in insulin treated diabetes mellitus. Diabetologia 1978; 15: 87–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Levin ME; Boisseau VC, Avioli LV. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med 1976; 294: 241–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Pascual J, Argente J, Lopez MB, et al. Bone mineral density in children and adolescents with diabetes mellitus type 1 of recent onset. Calcif Tissue Int 1998; 62: 31–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Liu EY, Wactawski-Wende J, Donahue RP, Dmochowski J, Hovey KM, Quattrin T. Does low bone mineral density start in post-teenage years in women with type 1 diabetes? Diabetes Care 2003; 26: 2365–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Ingberg CM, Palmer M, Aman J, Arvidsson B, Schvarcz E, Berne C. Body composition and bone mineral density in longstanding type 1 diabetes. J Intern Med 2004; 255: 392–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Bridges MJ, Moochhala SH, Barbour J, Kelly CA. Influence of diabetes on peripheral bone mineral density in men: a controlled study. Acta Diabetol 2005; 42: 82–6.PubMedCrossRefGoogle Scholar
  30. 30.
    López-Ibarra PJ, Pastor MM, Escobar-Jiménez F, et al. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endocr Pract 2001; 7: 346–51.PubMedCrossRefGoogle Scholar
  31. 31.
    Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 2000; 23: 295–303.PubMedGoogle Scholar
  32. 32.
    Tuominen JT, Impivaara O, Puukka P, Rönnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999; 22: 1196–200.PubMedCrossRefGoogle Scholar
  33. 33.
    Hampson G, Evans C, Petitt RJ, et al. Bone mineral density, collagen type 1 alpha 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia 1998; 41: 1314–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Selby PL. Osteopenia and diabetes. Diabet Med 1988; 5: 423–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Roe TF, Mora S, Costin G, Kaufman F, Carlson ME, Gilsanz V. Vertebral bone density in insulin-dependent diabetic children. Metabolism 1991; 40: 967–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Forsen L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 1999; 42: 920–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Ivers RQ, Cumming RG, Mitchell P, Peduto AJ. Diabetes and risk of fracture: the Blue Mountains Eye Study. Diabetes Care 2001; 24: 1198–203.PubMedCrossRefGoogle Scholar
  38. 38.
    Melchior TM, Sorensen H, Torp-Pedersen C. Hip and distal arm fracture rates in peri- and postmenopausal insulin-treated diabetic females. J Intern Med 1994; 236: 203–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol 1993; 137: 1203–11.PubMedGoogle Scholar
  40. 40.
    Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in post-menopausal women. Diabetes Care 2001; 24: 1192–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 2005; 289: E735–45.PubMedCrossRefGoogle Scholar
  42. 42.
    Bouillon R. Diabetic bone disease. Low turnover osteoporosis related to decreased IGF-I production. Verh K Acad Geneeskd Belg 1992; 54: 365–91.PubMedGoogle Scholar
  43. 43.
    Verhaeghe J, Van Herck E, Visser WJ, et al. Bone and mineral metabolism in BB rats with long-term diabetes. Diabetes 1990; 39: 477–82.PubMedCrossRefGoogle Scholar
  44. 44.
    Kitamura T, Kitamura Y, Nakae J, et al. Mosaic analysis of insulin receptor function. J Clin Invest 2004; 113: 209–19.PubMedGoogle Scholar
  45. 45.
    Jiang J, Lichtler AC, Gronowicz GA, et al. Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. Bone 2006; 39: 494–504.PubMedCrossRefGoogle Scholar
  46. 46.
    Bouillon R. Diabetic bone disease. Calcif Tissue Int 1991; 48: 155–60.CrossRefGoogle Scholar
  47. 47.
    Waud CE, Marks Jr SC, Lew R, Baran DT. Bone-mineral density in the femur and lumbar vertebrae decreases after twelve weeks of diabetes in spontaneous diabetic-prone BB/Worcester rats. Calcif Tissue Int 1994; 54: 237–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Bjorgaas M, Haug E, Johnsen HJ. The urinary excretion of deoxypyridinium cross-links is higher in diabetic than in nondiabetic adolescents. Calcif Tissue Int 1999; 65: 121–4.PubMedCrossRefGoogle Scholar
  49. 49.
    Loder RT. The influence of diabetes mellitus on the healing of closed fractures. Clin Orthopedics 1988; 232: 210–6.Google Scholar
  50. 50.
    Krakauer JC, McKenna MJ, Rao DS, Whitehouse FW. Bone mineral density in diabetes. Diabetes Care 1997; 20: 1339–40.PubMedGoogle Scholar
  51. 51.
    Munoz-Torres M, Fódar E, Escobar-Jiménez F, López-Ibarra PJ, Luna JD. Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcif Tissue Int 1996; 58: 316–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Kayath MJ, Dib SA, Vieiaa JG. Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabetes Complications 1994; 8: 97–104.PubMedCrossRefGoogle Scholar
  53. 53.
    Mathiassen B, Nielsen S, Ditzel J, Rodbro P. Long-term bone loss in insulin-dependent diabetes mellitus. J Intern Med 1990; 227: 325–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Rix M, Andreassen H, Eskildsen P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 1999; 22: 827–31.PubMedCrossRefGoogle Scholar
  55. 55.
    Forst T, Pfützner A, Kann P, et al. Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 1995; 12: 874–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes 1995; 44: 775–82.PubMedCrossRefGoogle Scholar
  57. 57.
    Campos Pastor MM, López-Ibarra PJ, Escobar-Jiménez F, Serrano Pardo MD, Garcia-Cervignón AG. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 2000; 11: 455–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Raskin P, Stevenson MR, Barilla DE, Pak CY. The hypercalciuria of diabetes mellitus: its amelioration with insulin. Clin Endocrinol (Oxf) 1978; 9: 329–35.CrossRefGoogle Scholar
  59. 59.
    Nagasaka S, Murakami T, Ucchikawa T, Ishikawa SE, Saito T. Effect of glycemic control on calcium and phosphorus handling and parathyroid hormone level in patients with non-insulin-dependent diabetes mellitus. Endocr J 1995; 42: 377–83.PubMedCrossRefGoogle Scholar
  60. 60.
    Okazaki R, Totsuka Y, Hamano K, et al. Metabolic improvement of poorly controlled non-insulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 1997; 82: 2915–20.PubMedCrossRefGoogle Scholar
  61. 61.
    Gunczler P, Lanes R, Paoli M, Martinis R, Villaroel O, Weisinger JR. Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2001; 14: 525–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Clowes JA, Khosla S, Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res 2005; 20: 1497–506.PubMedCrossRefGoogle Scholar
  63. 63.
    Henriksen DB, Alexandersen P, Bjamason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18: 2180–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000; 141: 1228–35.PubMedCrossRefGoogle Scholar
  65. 65.
    Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 2001; 177: 35–41.PubMedCrossRefGoogle Scholar
  66. 66.
    Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 2000; 21: 495–502.PubMedCrossRefGoogle Scholar
  67. 67.
    Isaia G, Bodrato L, Carlevatto V, Musetta M, Salamono G, Molinatti, GM. Osteoporosis in type II diabetes. Acta Diabetol Lat 1987; 24: 305–10.PubMedCrossRefGoogle Scholar
  68. 68.
    Haffner SM, Bauer RI. The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. Metabolism 1993; 6: 735–8.CrossRefGoogle Scholar
  69. 69.
    Buysschaert M, Cauwe F, Jarmart J, et al. Proximal femur density in type I and type II diabetic patients. Diabete Metab 1992; 18: 32–7.PubMedGoogle Scholar
  70. 70.
    Kao CH, Tsou CT, Chen CC Wang SJ. Bone-mineral density in patients with non-insulin-dependent diabetes mellitus by dual photon absorptiometry. Nucl Med Commun 1993; 14: 373–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Okuno YY, Nishizawa, Sekiya K, Hagiwara S, Miki T, Horii H. Total and regional bone mineral content in patients with non-insulin dependent diabetes mellitus. J Nutr Sci Vitamnol 1991; 37: 43–9.CrossRefGoogle Scholar
  72. 72.
    Sosa M, Dominguez M, Navarro MC, et al. Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. J Diabetes Complications 1996; 10: 201–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Avery L. Diabetes mellitus type 1 and 2: an overwiew. Nursing Stand 1998; 13: 35–8.Google Scholar
  74. 74.
    Barett-Connor E, Holbrook TL. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA 1992; 268: 3333–7.CrossRefGoogle Scholar
  75. 75.
    Wakasuigi M, Wakao M, Tawata M, Gan MN, Koizumi K, Onaya T. Bone-mineral density measured by dual energy X-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone 1993; 14: 29–33.CrossRefGoogle Scholar
  76. 76.
    van Daele PLA, Stolk RP, Burger H, et al. Bone density in non-insulin-dependent diabetes mellitus: the Rotterdam Study. Ann Intern Med 1995; 122: 409–14.PubMedCrossRefGoogle Scholar
  77. 77.
    Johnston CC, Hui SL, Longcope C. Bone mass and sex steroid concentrations in postmenopausal Caucasian diabetics. Metabolism 1985; 34: 544–50.PubMedCrossRefGoogle Scholar
  78. 78.
    Dobnig H, Piswanger-Sölkner JC, Roth M, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 2006; 91: 3355–63.PubMedCrossRefGoogle Scholar
  79. 79.
    Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol Rev 1997; 19: 244–57.PubMedCrossRefGoogle Scholar
  80. 80.
    Heath H, Melton LJ, Chu CP. Diabetes mellitus and risk of skeletal fracture. N Engl J Med 1980; 303: 567–70.PubMedCrossRefGoogle Scholar
  81. 81.
    Menczel J, Makin M, Robin G, Jaye I, Naor E. Prevalence of diabetes mellitus in Jerusalem. Israel J Med Sci 1972; 8: 918–9.PubMedGoogle Scholar
  82. 82.
    Paganini-Hill A, Ross RK, Gerkings VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981; 95: 28–31.PubMedCrossRefGoogle Scholar
  83. 83.
    Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767–73.PubMedCrossRefGoogle Scholar
  84. 84.
    Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001; 86: 32–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205–10.PubMedCrossRefGoogle Scholar
  86. 86.
    LaCroix AZ, Cauley JA, Pettinger M, et al. Statin menopausal women: results from the Women’s Health Initiative observation- al study. Ann Intern Med 2004; 139: 97–104.CrossRefGoogle Scholar
  87. 87.
    Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145: 401–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Lecka-Czernik B, Suva LJ, Gaddy D, Rzonca SO. Glitazones, the anti-diabetic PPAR-gamma agonists, pose a significant risk of bone loss: differential effects of rosiglitazone and netoglitazone (Abstract). J Bone Miner Res 2003; 18 (Suppl. 2): S24.Google Scholar
  89. 89.
    Kaye SA, Folsom AR, Sprafka JM, Prineas RJ, Wallace RB. Increased incidence of diabetes mellitus in relation to abdominal adiposity in older women. J Clin Epidemiol 1991; 44: 329–34.PubMedCrossRefGoogle Scholar
  90. 90.
    Vogt MT, Cauley JA, Kuller LH, Nevitt MC. Bone mineral density and blood flow to the lower extremities. J Bone Miner Res 1997; 12: 283–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Nevitt MC. Epidemiology of osteoporosis. Rheum Dis Clinc North Am 1994; 2: 535–9.Google Scholar
  92. 92.
    Wallace C, Reiber GE, LeMaster J, et al. Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer. Diabetes Care 2002; 24: 1983–6.CrossRefGoogle Scholar
  93. 93.
    Thalassinos NC, Hadjiyanni P, Tzaneia M, Alevizaki, C, Philokiprou D. Calcium metabolism in diabetes mellitus: effect of improved blood glucose control. Diabet Med 1993; 10: 341–4.PubMedCrossRefGoogle Scholar
  94. 94.
    Selby PI, Shearing PA, Marshall SM. Hydroxyproline excretion is increased in diabetes mellitus and related to the presence of microalbuminuria. Diabet Med 1995; 12: 240–3.PubMedCrossRefGoogle Scholar
  95. 95.
    Stepán J, Havránek T, Formánková J, Skrha J, Skrha F, Pacovsky V. Bone isoenzyme of serum alkaline phosphatase in diabetes mellitus. Clin Chim Acta. 1980; 105: 75–81.PubMedCrossRefGoogle Scholar
  96. 96.
    Bouillon R, Bex M, Van Herck E, et al. Influence of age, sex and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab 1995; 80: 1194–202.PubMedCrossRefGoogle Scholar
  97. 97.
    Gallacher SJ, Fenner JA, Fisher BM, et al. An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus. Diabet Med 1993; 10: 129–33.PubMedCrossRefGoogle Scholar
  98. 98.
    Sayinalp S, Gedik O, Koray Z. Increasing serum osteocalcin after glycemic control in diabetic men. Calcif Tissue Int 1995; 57: 422–5.PubMedCrossRefGoogle Scholar
  99. 99.
    Ryo O, Yasuo T, Kumiko H, et al. Metabolic improvemet of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 1997; 82: 2915–21.CrossRefGoogle Scholar
  100. 100.
    Stein GS, Lian JB. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 1993; 14: 424–42.PubMedGoogle Scholar
  101. lOl.
    Tomasek JJ, Meuers SW, Basinger JB, Green DJ, Shew RL. Diabetic and age-related enhancement of collagen-linked fluorescence in cortical bones of rats. Life Sci 1994; 55: 855–61.PubMedCrossRefGoogle Scholar
  102. 102.
    Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 1996; 11: 931–7.PubMedCrossRefGoogle Scholar
  103. 103.
    Fong Y, Edelstein D, Wang EA, Brownlee M. Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats. Diabetologia 1993; 36: 802–7.PubMedCrossRefGoogle Scholar
  104. 104.
    Miyata T, Notoya K, Yoshida K, et al. Advanced glycation end- products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalised bone particles. J Am Soc Nephrol 1997; 8: 260–70.PubMedGoogle Scholar
  105. 105.
    Takagi M, Kasayama S, Yamamoto T, et al. Advanced glycation endproducts stimulate interleukin-6 production by human bonederived cells. J Bone Miner Res 1997; 12: 439–46.PubMedCrossRefGoogle Scholar
  106. 106.
    Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006; 17: 1514–23.PubMedCrossRefGoogle Scholar
  107. 107.
    Schäffler A, Müller-Ladner U, Schölmerich J, Büchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006; 27: 449–67.PubMedCrossRefGoogle Scholar
  108. 108.
    Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999; 140: 1630–8.PubMedCrossRefGoogle Scholar
  109. 109.
    Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res 2002; 17: 200–9.PubMedCrossRefGoogle Scholar
  110. 110.
    Thommesen L, Stunes AK, Monjo M, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 2006; 99: 824–34.PubMedCrossRefGoogle Scholar
  111. 111.
    Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939–49.PubMedCrossRefGoogle Scholar
  112. 112.
    Nagi DK, Hendra TJ, Ryle AJ, et al. The relationships of concentrations of insulin, intact proinsulin and 32–33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-depen- dent) diabetic subjects. Diabetologia 1990; 33: 532–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Wakasugi M, Wakao RM, Tawata M, Gan N, Koizumi K, Onaya T. Bone mineral density in patients with hyperthyroidism measured by dual energy X-ray absorptiometry. Clin Endocrinol (Oxf) 1994; 40: 281.CrossRefGoogle Scholar
  114. 114.
    Jehle PM, Jehle DR, Mohan S, Böhm BO. Serum levels of insulin-like growth factor system components and relationships to bone metabolism in type 1 and type 2 diabetes mellitus patients. J Endocrinol 1998; 159: 297–306.PubMedCrossRefGoogle Scholar
  115. 115.
    Espallargues M, Sampietro-Colom L, Estrada MD, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporosis Int 2001; 12: 811–22.CrossRefGoogle Scholar
  116. 116.
    Ferrucci L, Russo Cr, Lauretani F, Bandinelli S, Guralnik JM. A role for sarcopenia in late-life osteoporosis. Aging Clin Exp Res 2002; 14: 1–4.PubMedCrossRefGoogle Scholar
  117. 117.
    Maggi S, Lauretani F, Ferrucci L, et al. The quality of bone: a “magic natural alloy” Aging Clin Exp Res 2004: 16: 3–9.CrossRefGoogle Scholar

Copyright information

© Springer Internal Publishing Switzerland 2008

Authors and Affiliations

  • Alois Saller
    • 1
    Email author
  • Stefania Maggi
    • 1
  • Giovanna Romanato
    • 1
  • Paolo Tonin
    • 2
  • Gaetano Crepaldi
    • 1
  1. 1.Aging SectionCNR Institute of NeurosciencePadovaItaly
  2. 2.IRCCS San CamilloLido di VeneziaItaly

Personalised recommendations